Analysis Note

Clotting activity is determined by comparison to a standard curve produced using normal pooled human plasma

General description

Native coagulation factor IX from human plasma. Sold on the basis of plasma equivalent units. 100 plasma equivalent units are equal to 500 µg of Factor IX. In vivo, activation of Factor IX to IXa occurs via either the tissue factor/Factor VIIa complex (the extrinsic pathway), or Factor XIa (the intrinsic pathway). Activated Factor IXa, in a complex with Factor VIIa, can then convert Factor X to Xa, the catalytic component of the prothrombinase complex.

Native coagulation factor IX from human plasma. Sold on the basis of plasma equivalent units. 100 plasma equivalent units are equal to 500 µg of Factor IX. In vivo, activation of Factor IX to IXa occurs via either the tissue factor/Factor VIIa complex (the extrinsic pathway), or Factor XIa (the intrinsic pathway). Activated Factor IXa, in a complex with Factor VIIIa, can then convert Factor X to Xa, the catalytic component of the prothrombinase complex.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Packaging

100 u in Plastic ampoule

Please refer to vial label for lot-specific concentration.

Physical form

In 100 mM NaCl, 20 mM Tris-HCl, 1 mM benzamidine, pH 7.5.

Preparation Note

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Reconstitution

Following initial thaw, aliquot and freeze (-70°C).

Warning

Toxicity: Standard Handling (A)